<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJEpi</journal-id><journal-title-group><journal-title>Open Journal of Epidemiology</journal-title></journal-title-group><issn pub-type="epub">2165-7459</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojepi.2021.112015</article-id><article-id pub-id-type="publisher-id">OJEpi-109267</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Outcome of Epidemiological Investigation of COVID-19 Outbreak in a South West State of Nigeria, March to August 2020
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Elvis</surname><given-names>Efe Isere</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Adewale</surname><given-names>Moses Adejugbagbe</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Aderonke</surname><given-names>Tolulope Fagbemi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Stephen</surname><given-names>Fagbemi</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Adekunle</surname><given-names>Gboyega Famokun</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Temitope</surname><given-names>Olajumoke Omoju</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Wahab</surname><given-names>Adegbenro</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>Nigeria Field Epidemiology and Laboratory Training Programme, Abuja, Nigeria</addr-line></aff><aff id="aff2"><addr-line>Department of Community Medicine, University of Medical Sciences, Ondo, Nigeria</addr-line></aff><aff id="aff3"><addr-line>Ondo State Ministry of Health, Akure, Nigeria</addr-line></aff><aff id="aff1"><addr-line>Department of Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria</addr-line></aff><pub-date pub-type="epub"><day>31</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>163</fpage><lpage>177</lpage><history><date date-type="received"><day>16,</day>	<month>February</month>	<year>2021</year></date><date date-type="rev-recd"><day>21,</day>	<month>May</month>	<year>2021</year>	</date><date date-type="accepted"><day>24,</day>	<month>May</month>	<year>2021</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background: On 3&lt;sup&gt;rd&lt;/sup&gt; April 2020, an outbreak of Coronavirus disease-2019 (COVID-19) was confirmed in Ondo State, Southwest Nigeria. Field investigations were conducted by the State Ministry of Health (MoH) to identify and confirm additional cases. This paper provides the outcome of the epidemiological investigation of the outbreak to further guide outbreak response activities. Methods: Field epidemiology methods coordinated by the State Public Health Emergency Operations Center (PHEOC) were used in the outbreak investigation. Suspected cases were reported through the routine Integrated Disease Surveillance and Response (IDSR) network in the State. Also, active case search/finding to communities and health facilities using the operational case definitions was conducted. Furthermore, the state COVID-19 emergency call center was established with toll-free phone number provided to members of the public to call-in to report suspected persons with symptoms consistent with the COVID-19 operational case definition (signal). All cases reported were investigated with nasopharyngeal sample collected and confirmatory testing for COVID-19 done by real-time polymerase chain reaction (RT-PCR) in a national reference laboratory. Information of each case investigated was documented using the COVID-19 case investigation form and COVID-19 line-list which captured socio-demographic characteristics, history of exposure to COVID-19, presenting symptoms, travel history and sample collection details. Data were extracted from the case investigation form and line list and analyzed using SPSS version 20, with a p-value set at &lt; 0.05. Results: A total of 4353 suspected cases were reported and investigated, of which 1316 cases were confirmed between March 19, 2020 and August 9, 2020. The mean age of the confirmed cases was 37.8 &#177; 14.8 years. The highest proportion of COVID-19 cases and deaths occurred in the age group 20 - 39 years (50.6%) and ≥60 years (13.5%), respectively. More males (52.4%) were affected than females (45.8%). There were 404 (30.7%) healthcare workers infection. About a quarter (325; 24.7%) of the cases was symptomatic and presented with key symptoms such as cough (98/325; 30.2%) and fever (74/325; 22.8%) during the investigation. A case fatality rate (CFR) of 2.2% was recorded in 7 of the 17 Local Government Areas (LGAs) where confirmed cases were reported in the State. Most of the confirmed cases, 1169 (88.8%) reside in urban LGAs of the State. The epidemic curve shows a propagated pattern of transmission with the outbreak reaching its peak on July 2, 2020. Significantly, higher proportion of death was recorded in the age group ≥ 60 years (14; 13.5%) and among males (26; 3.6%) (p &lt; 0.001). Conclusions: Our investigation found high transmission of COVID-19 infection among urban residents (LGAs) and health care workers with high mortality among males in older age group in the State. Hence, we recommend intensified risk communication and use of community structures to ensure compliance with public health COVID-19 preventive protocols including enforcing infection prevention and control compliance, particularly among high-risk groups.
 
</p></abstract><kwd-group><kwd>Coronavirus Disease 2019</kwd><kwd> Outbreak</kwd><kwd> Epidemiology</kwd><kwd> Ondo State</kwd><kwd> Nigeria</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Coronavirus disease-2019 (COVID-19) is an infectious disease caused by a newly discovered coronavirus called Severe Acute Respiratory Coronavirus 2 (SARS-CoV2) [<xref ref-type="bibr" rid="scirp.109267-ref1">1</xref>]. The SARS-CoV2 belongs to a family of viruses that cause illness with various symptoms such as pneumonia, fever, breathing difficulty and lung infections [<xref ref-type="bibr" rid="scirp.109267-ref2">2</xref>]. The virus is one of the main pathogens of respiratory infection alongside others such as SARSCoV and Middle East Respiratory Syndrome Coronavirus (MERSCoV) that caused severe respiratory syndrome in humans [<xref ref-type="bibr" rid="scirp.109267-ref3">3</xref>]. The term 2019 novel coronavirus was first used to refer to the virus that affected the lower respiratory tract of patients with pneumonia in a local Huanan South China Seafood market in Wuhan City, China on 29 December 2019 [<xref ref-type="bibr" rid="scirp.109267-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.109267-ref5">5</xref>]. Afterwards, the World Health Organization (WHO) announced the official name of the 2019 novel coronavirus to be coronavirus disease (COVID-19) [<xref ref-type="bibr" rid="scirp.109267-ref1">1</xref>].</p><p>The SARS-CoV2 has been understood to be zoonotic, however, no specific animal association has been identified [<xref ref-type="bibr" rid="scirp.109267-ref6">6</xref>]. Human to human transmission has been proven through small droplets expelled from the nose or mouth when a person with COVID-19 coughs, sneezes, or speaks [<xref ref-type="bibr" rid="scirp.109267-ref7">7</xref>]. The virus has been found to adhere to surfaces which act as fomites for the transmission of the disease [<xref ref-type="bibr" rid="scirp.109267-ref8">8</xref>]. The SARS-CoV2 presents in different ways which range from severe illness and mortality to mild symptoms and asymptomatic [<xref ref-type="bibr" rid="scirp.109267-ref9">9</xref>]. Early patterns of COVID-19 transmission have shown a trend similar to SARS and MERS coronaviruses however, unlike other coronaviruses, asymptomatic cases can still transmit the infection, which raises public health concerns [<xref ref-type="bibr" rid="scirp.109267-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.109267-ref11">11</xref>].</p><p>The COVID-19 outbreak is increasing and spreading rapidly globally, with over 20 million cases and 800,000 thousand deaths reported in 216 countries as on 28<sup>th</sup> August 2020 [<xref ref-type="bibr" rid="scirp.109267-ref12">12</xref>]. Since the report of the index case in Nigeria in February 2020 by the Nigeria Center for Disease Control (NCDC), daily records of confirmed cases have been reported in all states in the country, including Ondo State. As on 28<sup>th</sup> August 2020, a total of 53, 477 cases and 1011 deaths have been reported in Nigeria, while Ondo State ranked 11<sup>th</sup> among the states with high confirmed cases in the country [<xref ref-type="bibr" rid="scirp.109267-ref13">13</xref>].</p><p>This paper presents the outcome of the epidemiological investigation of COVID-19 outbreak in Ondo State, Nigeria from March to August 2020 to further guide the outbreak response activities.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Outbreak Settings</title><p>Ondo State is in the South-West Zone of Nigeria with her capital at Akure. The State is situated between longitudes 40,151E and 60,001E of the Greenwich median and latitudes 50,451N and 70,451N, which are to the North of the equator in the Southwestern geopolitical zones of the country. The surface area of the State is approximately 15,317 square kilometers and is bounded by Edo and Delta States on the east, Ogun and Osun States on the west, Ekiti and Kogi States on the north and Bight of Benin and the Atlantic Ocean on the South. The State consists of 18 Local Government Areas (LGAs) and 3 senatorial districts namely Ondo Central, North and South districts; and has a projected population of 5,205,141 in 2020 with an annual growth rate of 3% based on the 2006 population census [<xref ref-type="bibr" rid="scirp.109267-ref14">14</xref>]. The basic occupation by a vast majority of the population is farming, while other economic activities include small scale businesses, trading and civil service [<xref ref-type="bibr" rid="scirp.109267-ref15">15</xref>].</p></sec><sec id="s2_2"><title>2.2. Field Investigation</title><p>The investigation was conducted as part of outbreak control and response measures hence permission to conduct the study was obtained from the State Ministry of Health (SMoH).</p><p>Investigation commenced following an alert from clinicians at a government-owned Hospital, Akure on 30 March 2020 of a suspected case of COVID-19, a 34-year-old male with recent travel history to India. He arrived at Ondo State on 21st March 2020 and presented at the hospital with cough, sore throat and running nose with the onset of symptoms on 23<sup>rd</sup> March 2020. The State public health emergency Rapid Response Team (RRT) comprising of Commissioner for Health, State Epidemiologist, State and LGA surveillance officers, and health development partners in the state visited the hospital to investigate and implement public health response. Nasopharygeal and oropharyngeal samples were collected and tested for COVID-19 and returned positive from the national reference laboratory on the 3<sup>rd</sup> of April 2020.</p><p>The State Public Health Emergency Operation Center (PHEOC) was activated to coordinate the outbreak response. Furthermore, the state COVID-19 emergency call center was established with toll-free phone number provided to members of the public to call-in to report suspected persons with symptoms consistent with the COVID-19 operational case definition (signal) for investigation.</p><p>Using the COVID-19 operational case definitions developed by the Nigeria Center for Disease Control, active case search visits/case finding was conducted to communities and health facilities across the 18 local government areas (LGAs) by State RRT to identify additional suspected cases. All public health signals received through the State COVID-19 emergency call center were investigated with nasopharyngeal and oropharyngeal samples collected and transported under reverse cold chain temperatures (2˚C to 8˚C) to designated national reference laboratory for confirmatory testing for COVID-19 by real-time polymerase chain reaction (RT-PCR).</p><p>Furthermore, nasopharyngeal and oropharyngeal samples of close contacts of confirmed COVID-19 cases enrolled for 14-days contact follow-up exercise was collected and tested before they exit the follow-up exercise. Data of all cases investigated were documented using the national COVID-19 case investigation form and State COVID-19 line-list. The information documented were name, age/date of birth, gender, address/settlement and LGA of residence, occupation, clinical symptoms/presentations, date of onset of symptoms, travel history, sample collection details, phone contact and epidemiological exposures. Each case investigated was given an Epidemiological number as a unique identifier.</p></sec><sec id="s2_3"><title>2.3. Operational Definitions</title><p>During the onset of the outbreak, three categories of case definitions for COVID-19 were used to guide the outbreak investigations according to the NCDC guidelines [<xref ref-type="bibr" rid="scirp.109267-ref16">16</xref>].</p><p>Suspect case: 1) This is a patient with acute respiratory illness (fever and at least one sign/ symptom of respiratory disease (e.g., cough, shortness of breath) and a history of travel to or residence in a country/area or territory reporting local transmission of COVID-19 disease during the 14 days prior to symptom onset; 2) or a patient/health care worker with any acute respiratory illness and has been in contact with a confirmed COVID-19 case in the last 14 days prior to the onset of symptoms; 3) or a patient with a severe acute respiratory infection (fever and at least one sign/symptom of respiratory disease (e.g., cough, shortness of breath) and requiring hospitalization and with no other aetiology that fully explains the clinical presentation; 4) or a case for whom testing for COVID-19 is inconclusive.</p><p>Confirmed case: A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.</p><p>Probable case: Any suspected case for whom testing for COVID-19 is indeterminate test result or for whom testing was positive on a pan-coronavirus assay.</p></sec><sec id="s2_4"><title>2.4. Data Analysis</title><p>The State COVID-19 line-list and case investigation forms of all COVID-19 cases from 19<sup>th</sup> March to 9<sup>th</sup> August 2020 were retrieved from the state disease surveillance unit, information on key variables were extracted and exported into SPSS version 20 and analyzed. Descriptive statistics such as frequency table, mean (standard deviation) and charts were used to describe key variables including LGA, age, sex, occupation and education and clinical conditions of cases. The week of report of cases and outcomes was used to generate the epidemic curve. The Chi-square test was used to compare categorical variables including the socio-demographic characteristics, clinical condition and outcome of cases. Two-sided P-values &lt; 0.05 were considered statistically significant.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Socio-Demographic Characteristics of Cases</title><p>A total of 4353 suspected cases were reported and tested for COVID-19 of which 1316 COVID-19 cases were confirmed, with a case fatality rate of 2.2% recorded in 7 of the 17 LGAs which reported at least a confirmed case (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). Most of the confirmed cases (1169; 88.8%), reside in urban areas (LGAs) as shown in <xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="table" rid="table2">Table 2</xref>.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Distribution of confirmed cases by LGAs of residence in Ondo State March 19 to August 9, 2020</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >*LGA</th><th align="center" valign="middle" >Confirmed cases N = 1316</th><th align="center" valign="middle" >Death N = 29</th><th align="center" valign="middle" >*CFR</th></tr></thead><tr><td align="center" valign="middle" >Akure South</td><td align="center" valign="middle" >746</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >1.9%</td></tr><tr><td align="center" valign="middle" >Ondo West</td><td align="center" valign="middle" >171</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >3.5%</td></tr><tr><td align="center" valign="middle" >Okitipupa</td><td align="center" valign="middle" >131</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.3%</td></tr><tr><td align="center" valign="middle" >Owo</td><td align="center" valign="middle" >124</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.8%</td></tr><tr><td align="center" valign="middle" >Akure North</td><td align="center" valign="middle" >56</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.8%</td></tr><tr><td align="center" valign="middle" >Odigbo</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >4.5%</td></tr><tr><td align="center" valign="middle" >Akoko North East</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.0%</td></tr><tr><td align="center" valign="middle" >Ifedore</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >9.1%</td></tr><tr><td align="center" valign="middle" >Akoko South West</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.0%</td></tr><tr><td align="center" valign="middle" >Ose</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.0%</td></tr><tr><td align="center" valign="middle" >Ile-Oluji/Okeigbo</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.0%</td></tr><tr><td align="center" valign="middle" >Idanre</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.0%</td></tr><tr><td align="center" valign="middle" >Akoko North West</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.0%</td></tr><tr><td align="center" valign="middle" >Ese Odo</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.0%</td></tr><tr><td align="center" valign="middle" >Ilaje</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.0%</td></tr><tr><td align="center" valign="middle" >Akoko South East</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >50.0%</td></tr><tr><td align="center" valign="middle" >Irele</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >100.0%</td></tr><tr><td align="center" valign="middle" >Ondo East</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.0%</td></tr></tbody></table></table-wrap><p>*LGA = Local Government LGA = Local Government Area; CFR = Case Fatality Rate.</p><p><xref ref-type="table" rid="table2">Table 2</xref> shows the socio-demographic characteristics of confirmed cases of COVID-19 investigated. Most of the confirmed cases, 1110 (84.3%) were within the age group 20 to 59 years, with a mean age of 37.8 &#177; 14.8 years. Males (713; 54.2%) were more affected compare to females (603; 45.8) (<xref ref-type="table" rid="table2">Table 2</xref>). More than three quarters (1009; 76.7%) of the cases had a tertiary level of education. Health care workers (404; 30.7%) were most affected compared to other professionals as shown in <xref ref-type="table" rid="table2">Table 2</xref>.</p></sec><sec id="s3_2"><title>3.2. Admission and Clinical Conditions of Confirmed Cases</title><p>From <xref ref-type="table" rid="table3">Table 3</xref>, 88 (6.7%) of the confirmed cases were admitted as inpatient, while 325 (24.7%) were symptomatic. The first symptom reported by cases were as follows; 98 (30.2%) reported cough, fever (74; 22.8%), headache (30; 9.2%), runny nose (39; 12.0%), sore throat (24; 7.4%) and difficulty in breathing (15; 4.6%).</p><p><xref ref-type="fig" rid="fig2">Figure 2</xref> describes the epidemic curve of the outbreak from March to August 2020. The index case occurred on April 3, 2020. Thereafter, there was a surge in the number of confirmed COVID-19 cases with the outbreak reaching its peak on July 2, 2020. Afterwards, fluctuations in the number of cases were observed before a steady decline was recorded between August 3, 2020 and August 9, 2020.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Socio-demographic characteristics of respondents N = 1316</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variable</th><th align="center" valign="middle" >Frequency</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Age in years</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;5</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >1.4</td></tr><tr><td align="center" valign="middle" >5 - 19</td><td align="center" valign="middle" >84</td><td align="center" valign="middle" >6.4</td></tr><tr><td align="center" valign="middle" >20 - 39</td><td align="center" valign="middle" >666</td><td align="center" valign="middle" >50.6</td></tr><tr><td align="center" valign="middle" >40 - 59</td><td align="center" valign="middle" >444</td><td align="center" valign="middle" >33.7</td></tr><tr><td align="center" valign="middle" >60 - 79</td><td align="center" valign="middle" >96</td><td align="center" valign="middle" >7.3</td></tr><tr><td align="center" valign="middle" >≥80</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >0.6</td></tr><tr><td align="center" valign="middle" >Gender</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >713</td><td align="center" valign="middle" >54.2</td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >603</td><td align="center" valign="middle" >45.8</td></tr><tr><td align="center" valign="middle" >Location of cases</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Rural</td><td align="center" valign="middle" >147</td><td align="center" valign="middle" >11.2</td></tr><tr><td align="center" valign="middle" >Urban</td><td align="center" valign="middle" >1169</td><td align="center" valign="middle" >88.8</td></tr><tr><td align="center" valign="middle" >Type of Education</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >None</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >1.1</td></tr><tr><td align="center" valign="middle" >Nursery</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >0.6</td></tr><tr><td align="center" valign="middle" >Primary</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" >6.1</td></tr><tr><td align="center" valign="middle" >Secondary</td><td align="center" valign="middle" >204</td><td align="center" valign="middle" >15.5</td></tr><tr><td align="center" valign="middle" >Tertiary</td><td align="center" valign="middle" >1009</td><td align="center" valign="middle" >76.7</td></tr><tr><td align="center" valign="middle" >Occupation</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Health workers</td><td align="center" valign="middle" >404</td><td align="center" valign="middle" >30.7</td></tr><tr><td align="center" valign="middle" >Businessman and woman</td><td align="center" valign="middle" >225</td><td align="center" valign="middle" >17.1</td></tr><tr><td align="center" valign="middle" >Civil servant</td><td align="center" valign="middle" >168</td><td align="center" valign="middle" >12.8</td></tr><tr><td align="center" valign="middle" >Others</td><td align="center" valign="middle" >182</td><td align="center" valign="middle" >13.8</td></tr><tr><td align="center" valign="middle" >Pupil/Student</td><td align="center" valign="middle" >129</td><td align="center" valign="middle" >9.8</td></tr><tr><td align="center" valign="middle" >Political office Holders</td><td align="center" valign="middle" >77</td><td align="center" valign="middle" >5.9</td></tr><tr><td align="center" valign="middle" >Engineer</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >3.6</td></tr><tr><td align="center" valign="middle" >Religious/traditional leader</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >1.8</td></tr><tr><td align="center" valign="middle" >Banker</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >1.8</td></tr><tr><td align="center" valign="middle" >Security officer</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >2.7</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Admission and clinical conditions of confirmed cases</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Frequency</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Admitted as inpatient before lab testing</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >88</td><td align="center" valign="middle" >6.7</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >1228</td><td align="center" valign="middle" >93.3</td></tr><tr><td align="center" valign="middle" >Symptomatic</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >325</td><td align="center" valign="middle" >24.7</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >991</td><td align="center" valign="middle" >75.3</td></tr><tr><td align="center" valign="middle" >First symptom reported by respondents (n = 325)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Cough</td><td align="center" valign="middle" >98</td><td align="center" valign="middle" >30.2</td></tr><tr><td align="center" valign="middle" >Fever</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >22.8</td></tr><tr><td align="center" valign="middle" >Headache</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >9.2</td></tr><tr><td align="center" valign="middle" >Runny nose</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >12.0</td></tr><tr><td align="center" valign="middle" >Sore throat/pharyngitis</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >7.4</td></tr><tr><td align="center" valign="middle" >Difficulty breathing</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >4.6</td></tr><tr><td align="center" valign="middle" >New loss of taste</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >2.7</td></tr><tr><td align="center" valign="middle" >New loss of smell</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >2.5</td></tr><tr><td align="center" valign="middle" >Chest pain</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >2.2</td></tr><tr><td align="center" valign="middle" >General Body weakness</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >1.8</td></tr><tr><td align="center" valign="middle" >Others</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >4.6</td></tr><tr><td align="center" valign="middle" >Outcome</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Alive</td><td align="center" valign="middle" >1287</td><td align="center" valign="middle" >97.8</td></tr><tr><td align="center" valign="middle" >Dead</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >2.2</td></tr></tbody></table></table-wrap><p>Others = abdominal pain; chills/sweats; joint pain; inability to walk; Nausea.</p><p>Association between socio-demographic characteristics, clinical conditions and outcomes of cases</p><p><xref ref-type="table" rid="table4">Table 4</xref> below shows the association between the treatment outcomes with characteristics and clinical conditions of cases. A significant proportion of death occurred among cases within the age group 60 years and above (14; 13.5%) compared to other age groups (p &lt; 0.001). Death occurred among males (26; 3.6%) compared to the females (3; 0.5%) (p &lt; 0.001). Furthermore, symptomatic cases had higher proportion (27; 8.3%) of deaths compare to asymptomatic cases (2; 0.2%) (P &lt; 0.001). Among the symptomatic cases, a high proportion of death was found among those with difficulty in breathing (3; 20%), fever (11; 14.9%), new loss of taste (1; 11.1%), cough (9; 9.2%) and sore throat (2; 8.3%) (P &lt; 0.001)</p><table-wrap-group id="4"><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Association between socio-demographic characteristics and outcomes of cases</title></caption><table-wrap id="4_1"><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Variable</th><th align="center" valign="middle" >Outcome</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  rowspan="2"  >Total</th><th align="center" valign="middle"  rowspan="2"  >P-value</th></tr></thead><tr><td align="center" valign="middle" >Dead</td><td align="center" valign="middle" >Alive</td></tr><tr><td align="center" valign="middle" >Age in years</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;5</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >18 (100.0)</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >5 - 19</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >84 (100.0)</td><td align="center" valign="middle" >84</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >20 - 39</td><td align="center" valign="middle" >2 (0.3)</td><td align="center" valign="middle" >664 (99.7)</td><td align="center" valign="middle" >666</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >40 - 59</td><td align="center" valign="middle" >13 (2.9)</td><td align="center" valign="middle" >431 (97.1)</td><td align="center" valign="middle" >444</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥60</td><td align="center" valign="middle" >14 (13.5)</td><td align="center" valign="middle" >90 (86.5)</td><td align="center" valign="middle" >104</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Gender</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >26 (3.6)</td><td align="center" valign="middle" >687 (96.4)</td><td align="center" valign="middle" >713</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >3 (0.5)</td><td align="center" valign="middle" >600 (99.5)</td><td align="center" valign="middle" >603</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Location of cases</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Rural</td><td align="center" valign="middle" >5 (3.4)</td><td align="center" valign="middle" >142 (96.6)</td><td align="center" valign="middle" >147</td><td align="center" valign="middle" >0.294</td></tr><tr><td align="center" valign="middle" >Urban</td><td align="center" valign="middle" >24 (2.1)</td><td align="center" valign="middle" >1145 (97.9)</td><td align="center" valign="middle" >1169</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Type of Education</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >None</td><td align="center" valign="middle" >1 (6.7)</td><td align="center" valign="middle" >14 (93.3)</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >0.630</td></tr><tr><td align="center" valign="middle" >Nursery</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >8 (100.0)</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Primary</td><td align="center" valign="middle" >3 (3.8)</td><td align="center" valign="middle" >77 (96.2)</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Secondary</td><td align="center" valign="middle" >4 (2.0)</td><td align="center" valign="middle" >200 (98.0)</td><td align="center" valign="middle" >204</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Tertiary</td><td align="center" valign="middle" >21 (2.1)</td><td align="center" valign="middle" >988 (97.9)</td><td align="center" valign="middle" >1009</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Occupation</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Health workers</td><td align="center" valign="middle" >2 (0.5)</td><td align="center" valign="middle" >402 (99.5)</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Businessman and woman</td><td align="center" valign="middle" >14 (6.2)</td><td align="center" valign="middle" >211 (93.8)</td><td align="center" valign="middle" >225</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Civil servant</td><td align="center" valign="middle" >1 (0.6)</td><td align="center" valign="middle" >167 (99.4)</td><td align="center" valign="middle" >168</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Others</td><td align="center" valign="middle" >10 (5.5)</td><td align="center" valign="middle" >172 (94.5)</td><td align="center" valign="middle" >182</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Pupil/Student</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >129 (100.0)</td><td align="center" valign="middle" >129</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Politician</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >77 (100.0)</td><td align="center" valign="middle" >77</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="4_2"><table><tbody><thead><tr><th align="center" valign="middle" >Engineer</th><th align="center" valign="middle" >0 (0.0)</th><th align="center" valign="middle" >48 (100.0)</th><th align="center" valign="middle" >48</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >Religious/traditional ruler</td><td align="center" valign="middle" >2 (8.3)</td><td align="center" valign="middle" >22 (91.7)</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Banker</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >24 (100.0)</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Security officer</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >35 (100.0)</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Symptomatic</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >27 (8.3)</td><td align="center" valign="middle" >298 (91.7)</td><td align="center" valign="middle" >325</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >2 (0.2)</td><td align="center" valign="middle" >989 (99.8)</td><td align="center" valign="middle" >991</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >First symptom</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >N = 325</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Cough</td><td align="center" valign="middle" >9 (9.2)</td><td align="center" valign="middle" >89 (90.8)</td><td align="center" valign="middle" >98</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Fever</td><td align="center" valign="middle" >11 (14.9)</td><td align="center" valign="middle" >63 (85.1)</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Headache</td><td align="center" valign="middle" >1 (3.3)</td><td align="center" valign="middle" >29 (96.7)</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Running nose</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >39 (100.0)</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Sore throat</td><td align="center" valign="middle" >2 (8.3)</td><td align="center" valign="middle" >22 (91.7)</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >New loss of taste</td><td align="center" valign="middle" >1 (11.1)</td><td align="center" valign="middle" >8 (88.9)</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Difficulty in breathing</td><td align="center" valign="middle" >3 (20.0)</td><td align="center" valign="middle" >12 (80.0)</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >New loss of smell</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >5 (100.0)</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >*Others</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >31 (100.0)</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap></table-wrap-group><p>* Others = chest pain, diarrheoa, fatigue, joint pain, malaise, nausea, vomiting.</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>The finding in this investigation that a high proportion of the confirmed COVID-19 cases were males and between the age group of 20 to 59 years is consistent with previous studies in Oyo State, Nigeria [<xref ref-type="bibr" rid="scirp.109267-ref3">3</xref>] and Wuhan, China [<xref ref-type="bibr" rid="scirp.109267-ref17">17</xref>]. The high proportion of COVID-19 infection among the male age group could be attributed to the fact that this is an economically active age group, suggesting a potential role of socio-economic or work-related activities rather than immunological capacity. In the Nigeria system, men are more likely to engage in economic activities outside of the household and potentially become more exposed to SARS-CoV-2 infection than women [<xref ref-type="bibr" rid="scirp.109267-ref18">18</xref>]. Also, Bwire [<xref ref-type="bibr" rid="scirp.109267-ref19">19</xref>], De La Vega et al., [<xref ref-type="bibr" rid="scirp.109267-ref20">20</xref>] and Isere et al., [<xref ref-type="bibr" rid="scirp.109267-ref11">11</xref>] in their studies reported poor compliance and attitude towards COVID-19 preventive measures and protocol such as frequent hand washing, wearing of face mask, and stay at home orders among men compare to women.</p><p>Similarly, our investigation shows a high proportion of infection among healthcare workers which is consistent with a previous investigation by Usman et.al., [<xref ref-type="bibr" rid="scirp.109267-ref3">3</xref>]. This might be attributed to poor compliance to COVID-19 IPC protocol by health care workers due to key issues such as knowledge gaps and access to PPEs in the health care settings. This is of serious public health importance as it could potentially enhance disease transmission [<xref ref-type="bibr" rid="scirp.109267-ref21">21</xref>] and further weaken a health system that already struggles with insufficient human resources for health [<xref ref-type="bibr" rid="scirp.109267-ref18">18</xref>]. Also, the high proportion of infection among healthcare workers could also be attributed to poor level of preparedness for the COVID-19 outbreak in the health care settings, and this is also in consonance with the report of Elhadi et al., [<xref ref-type="bibr" rid="scirp.109267-ref22">22</xref>].</p><p>The epidemic curve of the outbreak suggests a propagated pattern of transmission of the disease. This is consistent with previous COVID-19 outbreak reports and studies in other regions of Nigeria NCDC [<xref ref-type="bibr" rid="scirp.109267-ref23">23</xref>], Usman et al., [<xref ref-type="bibr" rid="scirp.109267-ref3">3</xref>], Elimian et.al., [<xref ref-type="bibr" rid="scirp.109267-ref18">18</xref>] and in China by Chen et al., [<xref ref-type="bibr" rid="scirp.109267-ref24">24</xref>]. The pattern of the outbreak is suggestive of person-to-person transmission which further explains the findings in this investigation that most of the cases (88.8%) occurred in urban settings where crowded conditions, clustered settlement pattern of the houses and large-scale human interactions due to daily commercial activities could have facilitated the spread of the outbreak [<xref ref-type="bibr" rid="scirp.109267-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.109267-ref26">26</xref>].</p><p>The most common COVID-19 symptoms reported in our investigation were fever and cough. Grant et al., [<xref ref-type="bibr" rid="scirp.109267-ref27">27</xref>] and Tahvildari et al., [<xref ref-type="bibr" rid="scirp.109267-ref28">28</xref>] have reported similar findings from previous studies. Furthermore, the lower proportions of fever and cough reported in this study compared to other studies could be attributed to the fact that our investigation is a population-based study where symptoms were self-reported alongside testing, unlike previous studies where testing was limited to patients on admission at the hospital in the early phase of the outbreak [<xref ref-type="bibr" rid="scirp.109267-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.109267-ref28">28</xref>]. More importantly, fever which is one of the common symptoms reported in this investigation is often common in endemic febrile illnesses (malaria and Lassa fever) in Ondo State [<xref ref-type="bibr" rid="scirp.109267-ref18">18</xref>]. Hence, co-infection with these diseases could be responsible for the high report of fever as a symptom in this investigation compared to other symptoms.</p><p>The low case fatality rate (CFR) found in this study is consistent with that previous reports in the Nigeria [<xref ref-type="bibr" rid="scirp.109267-ref23">23</xref>] and other Africa countries such as South Africa and Senegal [<xref ref-type="bibr" rid="scirp.109267-ref12">12</xref>]. This could be associated with the mild to asymptomatic clinical presentation of most cases in this study who are more likely to recover from the infection [<xref ref-type="bibr" rid="scirp.109267-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.109267-ref29">29</xref>]. Also, our investigation shows a significantly high mortality rate among cases in the older age group who were mostly male compared to females. This sex-biased mortality could be attributed to sex differences in immune response as females are known to mount more robust innate, cell-mediated, and humoral immune response than males [<xref ref-type="bibr" rid="scirp.109267-ref30">30</xref>]. Sex chromosome constitution could also play an important role in disease outcome. Females have two copies of X chromosomes while males have one [<xref ref-type="bibr" rid="scirp.109267-ref31">31</xref>] [<xref ref-type="bibr" rid="scirp.109267-ref32">32</xref>] [<xref ref-type="bibr" rid="scirp.109267-ref33">33</xref>]. The X chromosome contains a high density of immune-related genes. Males and females show a distinct difference in immune system responses with females eliciting stronger immune responses to pathogens [<xref ref-type="bibr" rid="scirp.109267-ref31">31</xref>] [<xref ref-type="bibr" rid="scirp.109267-ref32">32</xref>] [<xref ref-type="bibr" rid="scirp.109267-ref33">33</xref>].</p><p>This difference in immune system responses may be a major contributing factor to viral load, disease severity, and mortality [<xref ref-type="bibr" rid="scirp.109267-ref30">30</xref>]. Also, differences in sex hormone milieus could be a determinant of viral infections as estrogen has immunoenhancing effects while testosterone has immunosuppressive effects [<xref ref-type="bibr" rid="scirp.109267-ref30">30</xref>]. The sex-specific severity of COVID-19 infection, however, indicates that further research on understanding the sex differences is needed [<xref ref-type="bibr" rid="scirp.109267-ref30">30</xref>].</p><p>Some key limitations of this investigation include misclassification bias as most cases were asymptomatic and their clinical presentations were not consistent with the surveillance operational case definition. However, a consistent review of the operational case definition using daily data generated from the field investigation assisted in minimizing misclassification bias. In addition, the data presented in this investigation is a preliminary finding of the outbreak investigation which might change with time as the outbreak is still ongoing. Finally, the epi-curve was generated using the week of report as opposed to the typical use of the date of onset of symptoms. This was because of the asymptomatic clinical status of most of the confirmed cases during the investigation. In addition, social desirability bias is suspected as community perception about the COVID-19 disease might have stigmatized respondents. However, probing questions were asked to ensure correct responses where possible.</p></sec><sec id="s5"><title>5. Conclusion</title><p>The outcome of this investigation indicates that high transmission among urban residence and health care workers are key public health concerns in the response to the COVID-19 outbreak in Ondo State, Nigeria. Furthermore, high case mortality among the older age groups requires public health intervention. Thus, we recommend intensified risk communication, enhanced surveillance activities, and use of community structures such as community and religious leaders, market and commercial vehicles associations, Ward Development Committee (WDC) and Village Development Committee (VDC) to ensure compliance with public health COVID-19 preventive measures particularly in the urban areas and among those facing a high risk of death. Furthermore, there is a need to prioritize public health interventions including training and vaccination among the vulnerable groups including health care workers who serve as front liners during case investigation, testing and case management.</p></sec><sec id="s6"><title>Authors’ Contributions</title><p>Author EEI conceived the study and statistical analysis plan. Author AMA and EEI did the statistical analysis and drafted the first draft of the manuscript under the supervision of ATF, SF, AGF, TOO and WA. All authors contributed to the interpretation of results and writing of the manuscript.</p></sec><sec id="s7"><title>Role of Funding Source</title><p>The study has no funder who played any role in any stage of the study.</p></sec><sec id="s8"><title>Ethical Approval</title><p>No ethical approval required given that the study was included in an outbreak investigation.</p></sec><sec id="s9"><title>Acknowledgements</title><p>The authors wish to appreciate all health care workers, surveillance officers, public health administrators and other stakeholders on the frontline in response to the COVID-19 outbreak in Ondo State especially field officers who through which the data for this study were generated.</p></sec><sec id="s10"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s11"><title>Cite this paper</title><p>Isere, E.E., Adejugbagbe, A.M., Fagbemi, A.T., Fagbemi, S., Famokun, A.G., Omoju, T.O. and Adegbenro, W. (2021) Outcome of Epidemiological Investigation of COVID-19 Outbreak in a South West State of Nigeria, March to August 2020. Open Journal of Epidemiology, 11, 163-177. https://doi.org/10.4236/ojepi.2021.112015</p></sec></body><back><ref-list><title>References</title><ref id="scirp.109267-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2020) Novel Coronavirus—China. https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/</mixed-citation></ref><ref id="scirp.109267-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Adhikari, S., Meng, S., Wu, Y.J., Mao, Y.P., Ye, R.X., Wang, Q.Z., Sun, C., Sylvia, S., Rozelle, S., Raat, H. and Zhou, H. (2020) Epidemiology, Causes, Clinical Manifestation and Diagnosis, Prevention and Control of Coronavirus Disease (COVID-19) during the Early Outbreak Period: A Scoping Review. Infectious Diseases of Poverty, 9, Article Number: 29. https://doi.org/10.1186/s40249-020-00646-x</mixed-citation></ref><ref id="scirp.109267-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Usman, A.B., Ayinde, O., Akinyode, A., Gbolahan, A. and Bello, B. (2020) Epidemiology of Coronavirus Disease 2019 (COVD-19) Outbreak Cases in Oyo State South West Nigeria, March-April 2020. Pan African Medical Journal, 35, Article No. 88. https://doi.org/10.11604/pamj.supp.2020.35.2.23832</mixed-citation></ref><ref id="scirp.109267-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Center for Disease Control (2020) Novel Coronavirus, Wuhan, China. https://www.cdc.gov/coronavirus/2019-nCoV/summary.html</mixed-citation></ref><ref id="scirp.109267-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., et al. (2020) Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The New England Journal of Medicine, 382, 1199-1207. https://doi.org/10.1056/NEJMoa2001316</mixed-citation></ref><ref id="scirp.109267-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2020) Novel Coronavirus-Japan (ex-China). https://www.who.int/csr/don/17-january-2020-novel-coronavirus-japan-ex-china/en/</mixed-citation></ref><ref id="scirp.109267-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2020) Q&amp;A on Coronaviruses (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-coronaviruses#:~:text=symptoms</mixed-citation></ref><ref id="scirp.109267-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">van Doremalen, N., Bushmaker, T., Morris, D.H., Holbrook, M.G., Gamble, A., Williamson, B.N., Tamin, A., et al. (2020) Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. The New England Journal of Medicine, 382, 1564-1567. https://doi.org/10.1056/NEJMc2004973</mixed-citation></ref><ref id="scirp.109267-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Center for Disease Control (2020) Coronavirus Disease 2019 (COVID-19): Symptoms of Coronavirus. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html?C 
DC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2 
Fabout%2Fsymptoms.html</mixed-citation></ref><ref id="scirp.109267-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Yu, P., Zhu, J., Zhang, Z., Han, Y. and Huang, L. (2020) A Familial Cluster of Infection Associated with the 2019 Novel Coronavirus Indicating Potential Person-to-Person Transmission during the Incubation Period. Journal of Infectious Diseases, 221, 1757-1761. https://doi.org/10.1093/infdis/jiaa077</mixed-citation></ref><ref id="scirp.109267-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Isere, E.E., Adejugbagbe, A.M., Oladoyin, V., Abiona, S. and Omorogbe, E.N. (2020) Pre-Symptomatic and Asymptomatic COVID-19 Cases in Nigeria Amidst Prevailing Socio-Cultural Beliefs and Practices: Implication for COVID-19 Transmission and Way Forward. Archive of Preventive Medicine, 5, 39-42.</mixed-citation></ref><ref id="scirp.109267-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2020) Weekly Operational Update on COVID-19—28 August 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/wou-28-august-approved.pdf?sfvrsn=d9e49c20_2</mixed-citation></ref><ref id="scirp.109267-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Nigeria Centre for Disease Control (2020) An Update of COVID-19 Outbreak in Nigeria. https://ncdc.gov.ng/diseases/sitreps/?cat=14&amp;name=An%20update%20of%20COVID-19%20outbreak%20in%20Nigeria</mixed-citation></ref><ref id="scirp.109267-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">National Bureau of Statistics (2020) 2017 Demographic Statistics Bulletin. https://nigerianstat.gov.ng/download/474</mixed-citation></ref><ref id="scirp.109267-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Isere, E.E., Fatiregun, A.A., Ilesanmi, O., Ijarotimi, I., Egube, B., Adejugbagbe, A. and Famokun, G. (2018) Lessons Learnt from Epidemiological Investigation of Lassa Fever Outbreak in a Southwest State of Nigeria December 2015 to April 2016. PLOS Current Outbreak, 10. https://doi.org/10.1371/currents.outbreaks.bc4396a6650d0ed1985d731583bf5ded</mixed-citation></ref><ref id="scirp.109267-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Nigeria Centre for Disease Control (2020) Case Definitions for Coronavirus Disease. https://ncdc.gov.in/WriteReadData/l892s/51329605621586240962.pdf</mixed-citation></ref><ref id="scirp.109267-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Wang, D., Yin, Y., Hu, C., Liu, X., Zhang, X., Zhou, S., Jian, M., Xu, H., Prowle, J., Hu, B., Li, Y. and Peng Z. (2020) Clinical Course and Outcome of 107 Patients Infected with the Novel Coronavirus, SARS-CoV-2, Discharged from Two Hospitals in Wuhan, China. Critical Care, 24, Article No. 188. https://doi.org/10.1186/s13054-020-02895-6</mixed-citation></ref><ref id="scirp.109267-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Elimian, K.O., Ochu, C.L., Ilori, E., Oladejo, J., Igumbor E., Steinhardt, L., et al. (2020) Descriptive Epidemiology of Coronavirus Disease 2019 in Nigeria, 27 February-6 June 2020. Epidemiology &amp; Infection, 148, Article No. e208. https://doi.org/10.1017/S095026882000206X</mixed-citation></ref><ref id="scirp.109267-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Bwire, G.M. (2020) Coronavirus: Why Men Are More Vulnerable to Covid-19 than Women? SN Comprehensive Clinical Medicine, 2, 874-876. https://doi.org/10.1007/s42399-020-00341-w</mixed-citation></ref><ref id="scirp.109267-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">de la Vega, R., Ruíz-Barquín, R., Boros, S. and Szabo, A. (2020) Could Attitudes toward COVID-19 in Spain Render Men More Vulnerable than Women? Global Public Health, 15, 1278-1291. https://doi.org/10.1080/17441692.2020.1791212</mixed-citation></ref><ref id="scirp.109267-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Barranco, R. and Ventura, F. (2020) Covid-19 and Infection in Healthcare Workers: an Emerging Problem. The Medico-Legal Journal, 88, 65-66. https://doi.org/10.1177/0025817220923694</mixed-citation></ref><ref id="scirp.109267-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Elhadi, M., Msherghi, A., Alkeelani, M., Zorgani, A., Zaid, A., Alsuyihili, A., Buzreg, A., et al. (2020) Assessment of Healthcare Workers’ Levels of Preparedness and Awareness Regarding COVID-19 Infection in Low-Resource Settings. American Journal of Tropical Medicine and Hygiene, 103, 828-833. https://doi.org/10.4269/ajtmh.20-0330</mixed-citation></ref><ref id="scirp.109267-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Nigeria Centre for Disease Control (2020) COVID-19 Situation Report 162. https://ncdc.gov.ng/themes/common/files/sitreps/c6bf4e88ec47ad023b2d5c631d03a49b.pdf</mixed-citation></ref><ref id="scirp.109267-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Chen, T., Guo, S. and Zhong, P. (2020) Epidemic Characteristics of the COVID-19 Outbreak in Tianjin, a Well-Developed City in China. American Journal of Infection Control, 48, 1068-1073. https://doi.org/10.1016/j.ajic.2020.06.006</mixed-citation></ref><ref id="scirp.109267-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization-Africa (2020) COVID-19 Pandemic Expands Reach in Africa. https://www.afro.who.int/news/covid-19-pandemic-expands-reach-africa</mixed-citation></ref><ref id="scirp.109267-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Neiderud, C.J. (2015) How Urbanization Affects the Epidemiology of Emerging Infectious Diseases. Infection Ecology &amp; Epidemiology, 5, Article No. 27060. https://doi.org/10.3402/iee.v5.27060</mixed-citation></ref><ref id="scirp.109267-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Grant, M.C., Geoghegan, L., Arbyn, M., Mohammed, Z., McGuinness, L., Clarke, E.L. and Wade, R.G. (2020) The Prevalence of Symptoms in 24,410 Adults Infected by the Novel Coronavirus (SARS-CoV-2; COVID-19): A Systematic Review and Meta-Analysis of 148 Studies from 9 Countries. PLoS ONE, 15, e0234765. https://doi.org/10.1371/journal.pone.0234765</mixed-citation></ref><ref id="scirp.109267-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Tahvildari, A., Arbabi, M., Farsi, Y., Jamshidi, P., Hasanzadeh, S., Calcagno, T.M., et al. (2020) Clinical Features, Diagnosis, and Treatment of COVID-19: A Systematic Review of Case Reports and Case Series. Frontiers in Medicine, 7, Article No. 231. https://doi.org/10.3389/fmed.2020.00231</mixed-citation></ref><ref id="scirp.109267-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Mi, Y., Huanga, T., Zhanga, J., Qin, Q., Gong, Y., Liu, S., Xue, H., Ning, C., Cao, L. and Cao, Y. (2020) Estimating the Instant Case Fatality Rate of COVID-19 in China. International Journal of Infectious Diseases, 97, 1-6. https://doi.org/10.1016/j.ijid.2020.04.055</mixed-citation></ref><ref id="scirp.109267-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Pradhan, A. and Olsson, P. (2020) Sex Differences in Severity and Mortality from COVID-19: Are Males More Vulnerable? Biology of Sex Differences. Biology of Sex Differences, 11, Article No. 53. https://doi.org/10.1186/s13293-020-00330-7</mixed-citation></ref><ref id="scirp.109267-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Klein, S.L. and Flanagan, K.L. (2016) Sex Differences in Immune Responses. Nature Reviews Immunology, 16, 626-638. https://doi.org/10.1038/nri.2016.90</mixed-citation></ref><ref id="scirp.109267-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Meier, A., Chang, J.J., Chan, E.S., Pollard, R.B., Sidhu, H.K., Kulkarni, S., Wen, T.F., Lindsay, R.J., Orellana, L., Mildvan, D., Bazner, S., Streeck, H., Alter, G., Lifson, J.D., Carrington, M., Bosch, R.J., Robbins, G.K. and Altfeld, M. (2009) Sex Differences in the Toll-Like Receptor-Mediated Response of Plasmacytoid Dendritic Cells to HIV-1. Nature Medicine, 15, 955-959. https://doi.org/10.1038/nm.2004</mixed-citation></ref><ref id="scirp.109267-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Hewagama, A., Patel, D., Yarlagadda, S., Strickland, F.M. and Richardson, B.C. (2009) Stronger Inflammatory/Cytotoxic T-Cell Response in Women Identified by Microarray analysis. Genes &amp; Immunity, 10, 509-516. https://doi.org/10.1038/gene.2009.12</mixed-citation></ref></ref-list></back></article>